{
  "id": 195053,
  "name": "BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO)",
  "slug": "biotechnology-innovation-organization-bio",
  "state": "DC",
  "description": "Trade association",
  "totalSpending": 2300000,
  "filings": 32,
  "yearlySpending": [
    {
      "year": 2018,
      "income": 240000
    },
    {
      "year": 2019,
      "income": 300000
    },
    {
      "year": 2020,
      "income": 240000
    },
    {
      "year": 2021,
      "income": 320000
    },
    {
      "year": 2022,
      "income": 320000
    },
    {
      "year": 2023,
      "income": 320000
    },
    {
      "year": 2024,
      "income": 320000
    },
    {
      "year": 2025,
      "income": 240000
    }
  ],
  "firms": [
    "ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)"
  ],
  "lobbyists": [
    "STEVEN IRIZARRY",
    "VINCENT ROBERTI, SR.",
    "DREW COLE",
    "LYDIA STRUNK",
    "CASEY DAVISON"
  ],
  "issues": [
    "TAX",
    "MMM",
    "ANI",
    "HCR",
    "BUD",
    "FUE",
    null,
    "DEF"
  ],
  "sampleDescriptions": [
    "- Biofuels, renewable chemicals/bio-based products",
    "- Issues related to reimbursement under Medicare Part B generally; Bipartisan Budget Act (H.R. 1892); Consolidated Appropriations Act (H.R. 1625)\n- Issues related to Medicare Part D, generally; Bipartisan Budget Act (H.R. 1892);  Consolidated Appropriations Act (H.R. 1625)\n- Medicaid; drug benefit design; pricing and rebates; and Section 1115 waivers",
    "- Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act of 2018; amendment on GE Salmon Labeling",
    "- Issued relating to the 340B Drug Pricing Program, including the 340B Protecting Access for the Underserved and Safety-Net Entities (PAUSE) Act (H.R. 4710); the Helping Ensure Low-income Patients have Access to Care and Treatment (HELP) Act (S. 2312); and the Ensuring the Value of the 340B Program Act (S. 2453)\n- Biodefense research, development and procurement issues; Pandemic All Hazards Preparedness Act (PAHPA) reauthorization; pandemic flu; MCM priority review voucher program\n- Issues related to biosimilars, generally; Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974/H.R. 2212)\n- Drug evaluation and review; compassionate use expanded access; Right to Try Act of 2017 (H.R. 878/S. 204); expedited pathways; innovation incentives; implementation of PDUFA IV and BSUFA II\n- Issues related to drug pricing and value, generally; Improving Access to Affordable Prescription Drug Act (S. 771)\n- Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)\n- Vaccines and infectious diseases; antimicrobials",
    "- Funding for Antimicrobial Resistance Programs\n- Funding for biofuels; Farm Bill Reauthorization \n- Funding for Biodefense and Emergency Preparedness Research, Development and Procurement, including reauthorization of the Pandemic All-Hazards Preparedness Act",
    "Vaccines and infectious diseases; antimicrobials",
    "Issues related to reimbursement under Medicare Part B generally\nIssues related to Medicare Part D, generally\nMedicaid; drug benefit design; pricing and rebates; and Section 1115 waivers",
    "Funding for Antimicrobial Resistance Programs\nFunding for biofuels; Farm Bill Reauthorization \nFunding for Biodefense and Emergency Preparedness Research, Development and Procurement, including reauthorization of the Pandemic All-Hazards Preparedness Act (PAHPA) (S. 2852/H.R. 6378)",
    "Issued relating to the 340B Drug Pricing Program, including the 340B Protecting Access for the Underserved and Safety-Net Entities (PAUSE) Act (H.R. 4710); the Helping Ensure Low-income Patients have Access to Care and Treatment (HELP) Act (S. 2312); and the Ensuring the Value of the 340B Program Act (S. 2453). \nBiodefense research, development and procurement issues; Pandemic All Hazards Preparedness Act (PAHPA) reauthorization; pandemic flu; MCM priority review voucher program\nIssues related to biosimilars, generally; Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974/H.R. 2212)\nIssues related to drug pricing and value, generally, including the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. \nIssues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469); and the Improving Access to Affordable Prescription Drugs Act (H.R. 1776/S. 771)",
    "Genetically engineered (GE) animals",
    "Biofuels, renewable chemicals/bio-based products",
    "Issues related to reimbursement under Medicare Part B generally\nIssues related to Medicare Part D, generally\nHHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs\nValue-based contracting and communications",
    "Funding for antimicrobial resistance programs\nFunding for renewable chemicals/bio-based products \nFunding for biodefense and emergency preparedness research, development and procurement, including reauthorization of the Pandemic All-Hazards Preparedness Act (PAHPA)",
    "Issued relating to the 340B Drug Pricing Program\nBiodefense research, development and procurement issues; Pandemic All Hazards Preparedness Act (PAHPA) reauthorization; pandemic flu; MCM priority review voucher program\nIssues related to biosimilars, generally; access to samples for testing; coding; naming; interchangeability and pharmacy substitution; Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act\nIssues related to drug pricing and value, generally, including the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. \nIssues related to the importation of prescription medicines, generally",
    "Issued relating to the 340B Drug Pricing Program\nBiodefense research, development and procurement issues; Pandemic All Hazards Preparedness Act (PAHPA) reauthorization; pandemic flu; MCM priority review voucher program\nIssues related to biosimilars, generally; access to samples for testing; coding; naming; interchangeability and pharmacy substitution; Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act\nIssues related to drug pricing and value, generally, including the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. \nIssues related to the importation of prescription medicines, generally\nIssues related to drug patents and patent reporting requirements",
    "Issues related to the Coronavirus Aid, Relief, and Economic Security (CARES) Act's SBA Paycheck Protection Program\nIssued relating to the 340B Drug Pricing Program\nBiodefense research, development, and procurement issues; Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization; pandemic flu; MCM priority review voucher program\nIssues related to biosimilars, generally; access to samples for testing; coding; naming; interchangeability and pharmacy substitution; Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act\nIssues related to drug pricing and value, generally, including the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. \nIssues related to the importation of prescription medicines, generally",
    "Funding for antimicrobial resistance programs\nFunding for renewable chemicals/bio-based products",
    "Issued relating to the 340B Drug Pricing Program\nBiodefense research, development and procurement issues; Pandemic All Hazards Preparedness Act (PAHPA) reauthorization; pandemic flu; MCM priority review voucher program\nIssues related to biosimilars, generally\nIssues related to drug pricing and value, generally  \nIssues related to the importation of prescription medicines, generally\nIssues related to drug patents and patent reporting requirements",
    "Issues related to reimbursement under Medicare Part B generally\nIssues related to Medicare Part D, generally\nValue-based contracting and communications",
    "Issues related to reimbursement under Medicare Part B \nIssues related to Medicare Part D, generally\nIssues related to Medicaid\nValue-based contracting and communications"
  ],
  "years": [
    2018,
    2019,
    2020,
    2021,
    2022,
    2023,
    2024,
    2025
  ],
  "growthRate": 0,
  "trajectory": "stable",
  "yearsActive": 8,
  "avgAnnualSpending": 287500,
  "peakYear": 2021,
  "lobbyistCount": 5,
  "firmCount": 1,
  "issueCount": 7,
  "industry": "technology"
}